ThromboGenics stops diabetic retinopathy trial due to slow enrollment

ThromboGenics N.V. (Euronext:THR) discontinued enrollment in the Phase II CIRCLE trial evaluating ocriplasmin (THR-409) to treat non-proliferative diabetic retinopathy (NPDR) due to slow recruitment rate, which ThromboGenics CEO Patrik De Haes attributed to "patients being unaware of their condition."

Last year, the study's protocol was amended to expand enrollment criteria and reduce the number of enrolled patients to 115 from 230 (see BioCentury, Jan. 12)...